DYADIC INTERNATIONAL INC (DYAI)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 966,630 | 393,572 | 1,957,500 | 385,896 |
| Foreign currency exchange loss | - | -7,072 | -5,995 | -3,146 |
| Cost of revenue | - | 297,658 | 395,894 | 301,956 |
| Research and development | 629,379 | 494,979 | 460,241 | 515,629 |
| General and administrative | 1,436,630 | 1,596,338 | 1,297,984 | 1,607,756 |
| Foreign currency exchange loss | 16,098 | - | - | - |
| Costs of research and development revenue | 148,457 | - | - | - |
| Costs of grant revenue | 465,134 | - | - | - |
| Total costs and expenses | 2,695,698 | 2,396,047 | 2,160,114 | 2,428,487 |
| Loss from operations | -1,729,068 | -2,002,475 | -202,614 | -2,042,591 |
| Interest expense | - | 113,562 | 88,833 | 88,634 |
| Interest income | - | 88,458 | 127,331 | 138,471 |
| Interest income | 49,127 | - | - | - |
| Interest expense-Related Party | 24,377 | - | - | - |
| Interest expense-Nonrelated Party | 89,456 | - | - | - |
| Gain on sale of alphazyme | - | - | - | - |
| Total other income (expense), net | -64,706 | -25,104 | -846 | -2,632 |
| Net loss | -1,793,774 | -2,027,579 | -203,460 | -2,045,223 |
| Basic net loss per common share | -0.06 | -0.07 | -0.01 | -0.07 |
| Diluted net loss per common share | -0.06 | - | - | - |
| Diluted weighted-average common shares outstanding | 30,102,324 | - | - | - |